This is the
talk page for discussing improvements to the
Joseph Jimenez article. This is not a forum for general discussion of the article's subject. |
Article policies
|
Find sources: Google ( books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL |
This article must adhere to the biographies of living persons (BLP) policy, even if it is not a biography, because it contains material about living persons. Contentious material about living persons that is unsourced or poorly sourced must be removed immediately from the article and its talk page, especially if potentially libellous. If such material is repeatedly inserted, or if you have other concerns, please report the issue to this noticeboard.If you are a subject of this article, or acting on behalf of one, and you need help, please see this help page. |
![]() | This article is rated Start-class on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||||||||||||||||||||||
|
![]() | It is requested that an image or photograph of Joseph Jimenez be
included in this article to
improve its quality. Please replace this template with a more specific
media request template where possible.
The Free Image Search Tool or Openverse Creative Commons Search may be able to locate suitable images on Flickr and other web sites. |
Hi, I'm Katya – a social media manager at Novartis. I'm aware of WP:COI and thus would like to raise to the community some portions of this article that I think could be improved.
It looks like Section 3.1 was simply copied and pasted in its entirety from the article on Novartis.
I'm not sure if this section should be here, for a number of reasons. The duplication seems to be redundant (especially as there's an extensive record of this information on the main Novartis article). Also, most of these controversies happened before Joseph Jimenez became CEO in 2010. Some of them even happened before he joined Novartis in 2007.
The last part of this section (3.1.6) has actually been cut from the main Novartis article. The court case is ongoing, so there’s no solid story yet. In the interests of NPOV, wouldn’t it be better to wait until the case is settled one way or the other before writing about it?
Finally, the Conflicts and Criticisms section is much, much larger than the rest of the article. Doesn't this constitute Undue Weight?
For the reasons listed above I’d recommend to remove the section 3.1. Please let me know what you think. Katya Reck ( talk) 14:57, 6 December 2013 (UTC)
![]() | This edit request by an editor with a conflict of interest has now been answered. |
Can you please update the "Novartis" section in the article to add, "Jimenez stepped down from the Board of Directors of startup uBiome in April 2019 to run his own venture fund." [1] [2] [3] [4] Naomi at Ruder Finn ( talk) 19:36, 17 June 2019 (UTC)
References
Date of birth is needed.-- 109.252.91.11 ( talk) 05:14, 8 November 2020 (UTC)
![]() | This edit request by an editor with a conflict of interest was declined. |
Joseph Jimenez serves on the boards of multiple companies and it would be great to create a new section called 'Board positions' after the 'Novartis' section. The information about his board positions is provided below, along with citations for each.
Can you please move the sentence "Jimenez joined the board of directors at General Motors on June 9, 2015 [1]." from the 'Novartis' section to the beginning of the 'Board positions' section?
Can you please add the below to the 'Board positions' section after the General Motors sentence:
Jimenez also has served on the Board of Directors of Procter & Gamble since 2018, where he is lead independent director [2]. He also serves as Chairman of Century Therapeutics, an iPSC derived allogeneic cell therapy company, and is on the Board of Graphite Bio, a gene therapy company [3] [4].
Isabelle at Ruder Finn ( talk) 17:15, 2 August 2022 (UTC)
References
![]() | This edit request by an editor with a conflict of interest has now been answered. |
Per the feedback provided above by Quetstar [1], I have revised the request and since I haven't heard back from Quetstar for a couple of weeks, I would like to re-submit this request to the general Talk page in the hopes that some other editor will review and publish these edits.
Can you please add the following information to the Careers section:
Jimenez joined the board of directors at General Motors on June 9, 2015 [2].
Jimenez also has served on the Board of Directors of Procter & Gamble since 2018, where he is lead independent director [3].
He also serves as Chairman of Century Therapeutics, an iPSC derived allogeneic cell therapy company, and is on the Board of Graphite Bio, a gene therapy company [4] [5].
Isabelle at Ruder Finn ( talk) 18:03, 19 August 2022 (UTC)
References
{{
cite web}}
: Missing or empty |title=
(
help); Text "Quetstar" ignored (
help)
{{
cite web}}
: Missing or empty |title=
(
help)
{{
cite web}}
: Missing or empty |title=
(
help)
{{
cite web}}
: Missing or empty |title=
(
help)
{{
cite web}}
: Missing or empty |title=
(
help)